Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
HR+
•
Breast Cancer, Non-metastatic
What factors influence whether you order OncotypeDx in HR+ node negative ILC?
Answer from: Medical Oncologist at Academic Institution
If there is differential ER/PR expression or other high risk features such as pleomorphic features or high grade.
Sign In
or
Register
to read more
6394
Related Questions
What approach is suggested for extended adjuvant endocrine therapy in a HR+ breast cancer?
Would you consider adding adjuvant ribociclib for a patient who has already received 2 years of endocrine therapy and is eligible for ribociclib according to the NATALEE trial?
What is your approach to adjuvant chemotherapy for a postmenopausal woman with pT1cN0 grade 2 ER+ breast cancer (IDC) and OncoType RS of 25?
What additional risk features, if any, would sway you to offer chemotherapy in premenopausal women with ER+ HER2- node positive patients whose Oncotype is < 11?
Would you offer adjuvant ribociclib to a postmenopausal female with ER+ luminal A, node+ breast cancer pT1cN1a grade 2 that didn't require chemotherapy per OncoType, but met NATALEE inclusion criteria?
What are your top takeaways in Medical Oncology from SABCS 2025?
What adjuvant therapy would you recommend for a woman in her 90s with ER-positive, HER2-positive breast cancer who received neoadjuvant trastuzumab, pertuzumab, and anastrozole, but did not achieve a pathologic complete response?
How would you treat a T2N1 ER 90%, PR 10%, HER-2 negative breast cancer in premenopausal women with a tumor abutting the pectoralis fascia with loss of fat plane, with a concern for a positive surgical margin?
Given the new ASCO guidelines on SNB in early stage breast cancer, how does the omission of SNB in patients aged 50-70 impact your adjuvant radiation recommendations?
What factors do you take into account when deciding which gene expression assay to utilize when making adjuvant treatment decisions in patients with non-metastatic breast cancer?